Home » Metabasis Gets Good News for Diabetes Treatment
Metabasis Gets Good News for Diabetes Treatment
Metabasis Therapeutics received promising results from its Phase IIa clinical trial of MB07803 for the treatment of Type 2 diabetes.
The drug was safe and well tolerated and met the study’s primary efficacy endpoint of a significant reduction in fasting plasma glucose (FPG). Administration of the drug at 200 mg resulted in a placebo-adjusted reduction in FPG from baseline of -28.9 mg/dL at day 28.
The drug regulates excess glucose production in the liver by inhibiting a key enzyme in the gluconeogenesis pathway. If approved, the product could serve as an alternative for diabetes patients who are unable to tolerate the current first-line therapy, metformin, Metabasis said.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May